GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Piotroski F-Score

Regenerex Pharma (Regenerex Pharma) Piotroski F-Score : 0 (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Regenerex Pharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Regenerex Pharma's Piotroski F-Score or its related term are showing as below:


Regenerex Pharma Piotroski F-Score Historical Data

The historical data trend for Regenerex Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Piotroski F-Score Chart

Regenerex Pharma Annual Data
Trend Nov09 Nov10 Nov11 Nov12 Nov13 Nov14 Mar17 Mar18 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenerex Pharma Quarterly Data
May14 Aug14 Nov14 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -0.046 + -0.186 + -2.801 + -0.264 = $-3.30 Mil.
Cash Flow from Operations was -0.003 + -0.121 + -0.172 + -0.1 = $-0.40 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(0.01 + 0.007 + 1.04 + 0.933 + 0.852) / 5 = $0.5684 Mil.
Total Assets at the begining of this year (Dec22) was $0.01 Mil.
Long-Term Debt & Capital Lease Obligation was $1.17 Mil.
Total Current Assets was $0.01 Mil.
Total Current Liabilities was $3.56 Mil.
Net Income was -0.048 + -0.023 + -0.018 + -0.049 = $-0.14 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep18)
to the end of last year (Dec22) was
(0.012 + 0.015 + 0.011 + 0.009 + 0.01) / 5 = $0.0114 Mil.
Total Assets at the begining of last year (Sep18) was $0.01 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.88 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Regenerex Pharma's current Net Income (TTM) was -3.30. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Regenerex Pharma's current Cash Flow from Operations (TTM) was -0.40. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-3.297/0.01
=-329.7

ROA (Last Year)=Net Income/Total Assets (Sep18)
=-0.138/0.012
=-11.5

Regenerex Pharma's return on assets of this year was -329.7. Regenerex Pharma's return on assets of last year was -11.5. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Regenerex Pharma's current Net Income (TTM) was -3.30. Regenerex Pharma's current Cash Flow from Operations (TTM) was -0.40. ==> -0.40 > -3.30 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.169/0.5684
=2.05665025

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep18 to Dec22
=0.212/0.0114
=18.59649123

Regenerex Pharma's gearing of this year was 2.05665025. Regenerex Pharma's gearing of last year was 18.59649123. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=0.009/3.56
=0.00252809

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=0.004/0.875
=0.00457143

Regenerex Pharma's current ratio of this year was 0.00252809. Regenerex Pharma's current ratio of last year was 0.00457143. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Regenerex Pharma's number of shares in issue this year was 277.919. Regenerex Pharma's number of shares in issue last year was 227.113. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Regenerex Pharma's gross margin of this year was . Regenerex Pharma's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/0.01
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep18)
=0/0.012
=0

Regenerex Pharma's asset turnover of this year was 0. Regenerex Pharma's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Regenerex Pharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Regenerex Pharma  (OTCPK:PEPT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Regenerex Pharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerex Pharma (Regenerex Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines